| Short Description : | Recombinant-HLA-A*02:01 NY-ESO-1 peptide complex is synthetically produced from the Human HLA-A*02:01 AA25-305/B2M protein AA2-119 sequence and is suitable for use in western blot applications. |
| Host: | HEK293 cells NA |
| Note: | STRICTLY FOR FURTHER RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Conjugation: | Unconjugated |
| Dilution Range: | A quick spin of the vial followed by reconstitution in distilled water to a concentration not less than 0.1 mg/mL. This solution can then be diluted into other buffers. NA |
| Formulation: | Lyophilised from 0.2 µm filtered PBS solution pH7.4 NA |
| Storage Instruction: | The lyophilized protein is stable for at least 2 years from date of receipt at-20°C C. NA |
| Endotoxin: | Endotoxin content was assayed using a LAL gel clot method. Endotoxin level was found to be less than 0.1 ng/µg (1EU/µg). NA |
| Accession Number: | P61769 |
| Immunogen: | DNA sequence encoding the Human (HLA-A*02:01) AA25-305 [accession# P04439] and the B2M protein AA2-119 [accession# P61769], fused to the mutant NY-ESO-1 epitope SLLMWITQC.This complex includes a C terminal polyHis and was expressed in HEK cells. NA |
| Immunogen Region: | Human HLA-A*02:01 AA25-305/B2M protein AA2-119 |